Table 7.

Factors associated with global protection one month after administration of 13-valent pneumococcal conjugate vaccine, by OPA and ELISA, among 38 HIV-infected subjects with CD4 cell count ≥200 cells/µl.

Variable	ELISA			OPA
	Odds ratio	Confidence interval	p	Odds ratio	Confidence interval	p
CD4 cell count > 750 cells/µl (median)	>999.99	<0.001->999.99	0.95	3.92	0.68-22.70	0.13
CD8 cell count > 800 cells/µl	0.59	0.05-7.17	0.68	0.69	0.14-3.40	0.64
CD4/CD8 ratio > 0.8	>999.99	<0.001->999.99	0.95	3.43	0.59-19.80	0.17
Plasma HIV RNA viral load, <40 copies/ml	21.33	1.47-310.01	0.025	8.40	1.11-63.73	0.04
Neutrophil count >3500cell/µl	1.50	0.12-18.12	0.75	2.62	0.45-15.16	0.28
CDC stage C	0.33	0.025-4.40	0.40	0.46	0.07-3.13	0.43
Age > 50 years	0.53	0.04-6.39	0.62	0.60	0.12-2.97	0.53
Body mass index (kg/m2)	1.09	0.09-13.30	0.95	0.88	0.17-4.45	0.87
CMV seropositivity	3.5	0.25-48.03	0.35	0.82	0.08-8.60	0.87
Time since HIV infection diagnosis	0.67	0.05-8.06	0.75	0.78	0.16-3.90	0.77
History of bacterial pneumonia	0.26	0.02-3.53	0.31	0.33	0.04-2.45	0.28
Nadir CD4 count cell/µL<200 cells/µl	0.20	0.02-2.46	0.21	0.18	0.03-0.96	0.04
Active tobacco use	1.33	0.11-16.14	0.82	0.58	0.12-2.79	0.50
Prior PPV23 vaccine	<0.001	<0.001->999.99	0.95	1.09	0.18-6.69	0.92

PPV23, 23-valent pneumococcal polysaccharide vaccine.

Globally protected was defined as a patient who developed a protection for at least five of the tested serotypes targeted by PCV13.

Bold values indicate p < 0.05.